Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;45(11):2357-2367.
doi: 10.1002/cbin.11685. Epub 2021 Aug 23.

MiR-26a-5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17

Hongtao Shi  1 , Hao Li  1 , Fan Zhang  1 , Honghong Xue  1 , Yanan Zhang  1 , Qinghua Han  1
Affiliations

MiR-26a-5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17

Hongtao Shi et al. Cell Biol Int. 2021 Nov.

Abstract

Cardiac hypertrophy has been a high prevalence rate throughout the world. It has posed a big threat to public health due to limited therapeutic approaches. Previous studies showed that pathological cardiac hypertrophy was associated with autophagy, microRNAs (miRNA), and other signaling pathways, while the molecular mechanisms remain incompletely characterized. In this study, we used thoracic aortic constriction (TAC)-induced mice and angiotensin-II (Ang-II)-induced H9C2 cell line as cardiac hypertrophy model to investigate the role of miR-26a-5p in cardiac hypertrophy. We found that miR-26a-5p was downregulated in cardiac hypertrophy mice. Overexpression of miR-26a-5p by type 9 recombinant adeno-associated virus (rAAV9) reversed the heart hypertrophic manifestations. The phenotypes were also promoted by miR-26a-5p inhibitor in Ang-II-induced H9C2 cells. Through miRNA profile analysis and dual-luciferase reporter assay, ADAM17 was identified as a direct target of miR-26a-5p. Restored expression of ADAM17 disrupted the effect of miR-26a-5p on cardiac hypertrophy. To sum up, these results indicated that miR-26a-5p played an inhibitory role in cardiac hypertrophy and dysfunction via targeting ADAM17. The miR-26a-5p-ADAM17-cardiac hypertrophy axis provided special insight and a new molecular mechanism for a better understanding of cardiac hypertrophy disease, as well as the diagnostic and therapeutic practice.

Keywords: ADAM17; MiR-26a-5p; cardiac hypertrophy.

PubMed Disclaimer

References

REFERENCES

    1. Ai, J., He, Y., Zheng, M., Wen, Y., Zhang, H., Huang, F., & Zhu, Y. (2018). Characterization of recombinant adeno-associated viral transduction and safety profiles in cardiomyocytes. Cellular Physiology and Biochemistry, 48, 1894-1900.
    1. Bye, A., Røsjø, H., Nauman, J., Silva, G. J., Follestad, T., Omland, T., & Wisløff, U. (2016). Circulating microRNAs predict future fatal myocardial infarction in healthy individuals-The HUNT study. Journal of Molecular and Cellular Cardiology, 97, 162-168.
    1. Cingolani, O. H., Yang, X. P., Cavasin, M. A., & Carretero, O. A. (2003). Increased systolic performance with diastolic dysfunction in adult spontaneously hypertensive rats. Hypertension, 41, 249-254.
    1. Cui, M., Shen, W., Qin, W., Wang, X., Li, Y., Xu, F., & Xin, Z. (2020). Circular RNA ciRS-7 promotes tube formation in microvascular endothelial cells through downregulation of miR-26a-5p. Journal of Biochemical and Molecular Toxicology, 34, e22468.
    1. Di Leva, G., Garofalo, M., & Croce, C. M. (2014). MicroRNAs in cancer. Annual review of pathology, 9, 287-314.

LinkOut - more resources